This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-267608-0odu8lus | imatinib[ 6, 40] Assessing the gold standard-- lessons from the history of RCTs Cancer clinical trials: the rear- view mirror and the crystal ball Adaptive designs for clinical trials chemisimilars and biosimilars: is clinical testing fit for purpose? |
| cord-267608-0odu8lus | retrospective cohort study Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? |
| cord-032607-bn8g02gi | : Stop describing and start fixing-the promise of longitudinal interventioncohorts Healthy Life Trajectories Initiative( HeLTI) Potential of'stacking'early childhood interventions to reduce inequities in learning outcomes Is stacking intervention components cost- effective? |
| cord-032607-bn8g02gi | Research ethics committee decision- making in relation to an efficient neonatal trial What influences recruitment to randomised controlled trials? |
| cord-004647-0fuy5tlp | A question- based approach to the analysis of safety data Adherence to therapy and adverse drug reactions: is there a link? |
| cord-316626-258rbcwb | cord-316626- 258rbcwb authors: Serpa Neto, Ary; Hodgson, Carol title: Will Evidence- based Medicine Survive the COVID-19 Pandemic? date: 2020- 09- 17 journal: Ann Am Thorac Soc DOI: 10.1513/ annalsats.202006- 587ed sha: a035066298674cb37cc294a2f37b883ebf5f852c doc_id: |
| cord-345095-1li57v0j | So, how do we run clinical trials in the time of COVID-19? |
| cord-135406-ztgrxucb | Epidemiology Does water kill? |
| cord-135406-ztgrxucb | The Consistency Statement in Causal Inference: A Definition or an Assumption? |
| cord-267699-h7ftu3ax | ( SARS- CoV-2) in Hospital Rooms of Infected Patients Aerodynamic characteristics and RNA concentration of SARS- CoV-2 aerosol in Wuhan hospitals during COVID-19 outbreak Respiratory protection for healthcare workers treating Ebola virus disease( EVD): Are facemasks sufficient to meet occupational health and safety obligations? |
| cord-267699-h7ftu3ax | A Systematic Review Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff Airborne or droplet precautions for health workers treating COVID-19? |
| cord-267699-h7ftu3ax | N95 or surgical masks? |
| cord-266573-vfl08i2p | But what role will payment play in encouraging trial participation- and what role should it play? |
| cord-266573-vfl08i2p | How should we think about offering payment to participants in these trials? |
| cord-266573-vfl08i2p | The continuing unethical conduct of underpowered clinical trials Paying research participants: regulatory uncertainty, conceptual confusion, and a path forward Payment for research participation: a coercive offer Undue inducement: nonsense on stilts? |
| cord-266573-vfl08i2p | This is also the more efficient approach; why spend resources on incentives that are unneeded? |
| cord-266573-vfl08i2p | What's the price of a research subject? |
| cord-294651-iy0h2pyf | The Lancet How will country- based mitigation measures influence the course of the COVID-19 epidemic? |
| cord-294651-iy0h2pyf | The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response How will country- based mitigation measures influence the course of the COVID-19 epidemic? |
| cord-294651-iy0h2pyf | medRxiv Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19( COVID-19) Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open- label, randomized No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial Should chloroquine and hydroxychloroquine be used to treat COVID-19? |
| cord-031978-l6nlrv9h | Says who? |
| cord-286144-6wtk5y7c | ( COVID-19): a review COVID-19 and risks to the supply and quality of tests, drugs, and vaccines Global coalition to accelerate COVID-19 clinical research in resource- limited settings Master protocols to study multiple therapies, multiple diseases, or both Adaptive clinical trials: advantages and disadvantages of various adaptive design elements Master protocols in clinical trials: a universal Swiss Army knife? |
| cord-286144-6wtk5y7c | A Rush to judgment? |
| cord-286144-6wtk5y7c | Master protocols in immuno- oncology: do novel drugs deserve novel designs? |
| cord-286144-6wtk5y7c | The SARS, MERS and novel coronavirus( COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? |
| cord-018677-gmitz3gg | And for how long are these beneficiaries entitled to receive the vaccine? |
| cord-018677-gmitz3gg | However, controversy surrounds the boundaries for the group of persons entitled to receive the investigational vaccine at the conclusion of the study-only participants in the trial, all persons living in the same region, or all persons living in the same country? |
| cord-018677-gmitz3gg | The Alaska H. influenzae Vaccine Study Group Efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera- endemicarea Global reduction of Hib disease: what are the next steps? |
| cord-018677-gmitz3gg | The safety, immunogenicity, and transmissibility of single- dose live oral cholera vaccine CVD 103-HgR in 25- 59 month old Indonesian children The ethical challenge of infection- inducing challenge experiments Infectious disease experimentation involving human volunteers Initial clinical evaluation of new vaccine candidates: investigators'perspective of phase I and phase II clinical trials of safety, immunogenicity, and preliminary efficacy Evaluating new vaccines for developing countries: efficacy or effectiveness? |
| cord-018677-gmitz3gg | When are placebo- controlled trials ethically acceptable? |
| cord-331206-m938suxh | A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic? |
| cord-026998-vlmoa5dr | And what should we do about it? |
| cord-026998-vlmoa5dr | Covid-19: what do we know so far about a vaccine? |
| cord-026998-vlmoa5dr | Do we really need detailed studies of the effect of the virus on practice in every conceivable specialty? |
| cord-026998-vlmoa5dr | Why is this happening? |
| cord-279197-cesemos0 | How will medical administrators view some of the staples of integrative cancer therapies in the next few years? |
| cord-279197-cesemos0 | Will administrators be eager to restart programs that rely on inperson services for high- risk patients? |
| cord-345762-khvcoqti | Can we increase the tempo of discovery while staying faithful to scientific method? |
| cord-345762-khvcoqti | So how can RCT be rendered more doable and informative during a pandemic? |
| cord-004339-7nwpic3d | Can the Sino- nasal Outcome Test( SNOT-22) be used as a reliable outcome measure for successful septal surgery? |
| cord-004339-7nwpic3d | Nasal septoplasty with submucosal diathermy to inferior turbinates improves symptoms at 3 months postoperatively in a study of one hundred and one patients Septoplasty for nasal obstruction due to a deviated nasal septum in adults: a systematic review Suturing of the nasal septum after septoplasty, is it an effective alternative to nasal packing? |
| cord-004339-7nwpic3d | Otolaryngol Head Neck Surg Does septoplasty enhance the quality of life in patients? |
| cord-004339-7nwpic3d | a suitable evaluation for septorhinoplasty? |
| cord-004339-7nwpic3d | can we make it more clinically meaningful? |
| cord-004339-7nwpic3d | demographics and perioperative outcomes Admitted Patient Care-England Nasal patency: problems in obtaining standard reference values for the surgeon Complications in septoplasty based on a large group of 5639 patients Is nasal packing necessary after septoplasty? |
| cord-344491-93ggxzxu | Path trial to be less burdensome relative to, for example, RCTs on effect of medications, due to the user- oriented approach emphasizing the investigation of the perspective"What matters to you? |
| cord-344491-93ggxzxu | The MOBID-2 pain scale: reliability and responsiveness to pain in patients with dementia Who suffers most? |
| cord-344491-93ggxzxu | The continuing process of communication should be initiated as early as possible in collaboration with the general practitioner as a comprehensive medical examination including revision of medications, enabling the PWD to clarify individual values and wishes for domestic and institutionalized treatment and care( i.e."What matters to you?"). |
| cord-344491-93ggxzxu | The relative stress scale, a useful instrument to identify various aspects of carer burden in dementia? |
| cord-344491-93ggxzxu | This individual perspective underlines the significance of user involvement, reflected in the trial's slogan: what matters to you? |
| cord-347189-i9rzo3j0 | At what cost to clinical trial enrollment? |
| cord-347189-i9rzo3j0 | Directive really improve clinical trial approval time? |
| cord-347189-i9rzo3j0 | Virtually perfect? |
| cord-347189-i9rzo3j0 | will the pandemic lead to change? |
| cord-309582-ihrj84hr | Performance of different clinical trial designs to evaluate treatments during an epidemic Ethical Rationale for the Ebola"Ring Vaccination"Trial Design Designing cell lines for viral vaccine production: Where do we stand? |
| cord-309582-ihrj84hr | The n- of-1 clinical trial: the ultimate strategy for individualizing medicine? |
| cord-350062-6xsh2pis | Can trial sequential monitoring boundaries reduce spurious inferences from meta- analyses? |
| cord-331487-jh34klbg | Interferon Responses Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-284502-nesvd10a | 3.5| Should COVID-19 screening be reported? |
| cord-279637-n8acd6hj | 90/220 Is it time to reform oversight of clinical gene therapy in the EU? |
| cord-331133-6zu44fn2 | In Drug Discovery, Development, and Evaluation Envisioning a Transformed Clinical Trials Enterprise in the United States Evaluability assessment to improve public health policies, programs, and practices Making research relevant: if it is an evidence- based practice, where's the practice- based evidence? |
| cord-331133-6zu44fn2 | What does the marriage of Open Access and online publication bring? |
| cord-331133-6zu44fn2 | Will we continue to use limited funds to support the currently slow and cumbersome research enterprise that produces costly results that may not be relevant or easily translated into practice, or are we willing to pursue alternative approaches that in other research disciplines have produced rapid and relevant improvements? |
| cord-327738-i400ynjp | COVID-19 outbreak Are we harming cancer patients by delaying their cancer surgery during the COVID-19 pandemic? |
| cord-327738-i400ynjp | Could the pandemic inappropriately skew the results? |
| cord-327738-i400ynjp | If we continue such clinical trials, are we putting patients at greater risk of COVID19-related complications? |
| cord-327738-i400ynjp | If we expedite and prioritize surgical treatment for those patients who are part of a trial, are we unduly pressuring them to participate( a form of coercion)? |
| cord-327738-i400ynjp | In contrast,, is it ethical to suspend future enrollment or active participation if it would potentially deny patients the benefit of novel therapeutic interventions or improved outcomes associated with the clinical trial? |
| cord-327738-i400ynjp | Specifically, is it ethically appropriate to continue enrollment and treatment of patients in clinical trials that include surgical intervention? |
| cord-327738-i400ynjp | What is the ethical basis for supporting this decision even though it means that some patients are not getting the latest and potentially more effective devices to treat their vascular disease? |
| cord-327738-i400ynjp | cord-327738-i400ynjp authors: Milner, Ross; Donington, Jessica; Matthews, Jeffrey; Posner, Mitchell; Turaga, Kiran; Angelos, Peter title: Is it Ethically Appropriate to Continue Surgical Clinical Trials During the COVID-19 Pandemic? |
| cord-326331-g4o3forj | Society of NeuroInterventional Surgery recommendations for the care of emergent neurointerventional patients in the setting of COVID-19 Letter: considerations for performing emergent neurointerventional procedures in a COVID-19 environment Preserving access: a review of stroke thrombectomy during the COVID-19 pandemic How will country- based mitigation measures influence the course of the COVID-19 epidemic? |
| cord-326331-g4o3forj | Virtually perfect? |
| cord-352177-05sku8a8 | Patient distrust in pharmaceutical companies: an explanation for women under- representation in respiratory clinical trials? |
| cord-310272-utqyuy0n | 20th Australasian conference on information systems ACIS What is IT in use and why does it matter for IS design? |
| cord-310272-utqyuy0n | But he is less content when it comes to how the tablet has been serving him during his rounds because the tablet acts like a barrier between him and his patients, which he consider as a restriction and prioritises ultimately achieving a better communication with the patients rather than his convenience("Who wants a medical student( someday physician) who focuses more on a computer than on the person?"). |
| cord-310272-utqyuy0n | Code saturation versus meaning saturation: How many interviews are enough? |
| cord-310272-utqyuy0n | Do electronic health records affect quality of care? |
| cord-310272-utqyuy0n | Eureka moments in the works of Claudio Ciborra Resist, comply or workaround? |
| cord-310272-utqyuy0n | How Lloyd Morgan's canon backfired Have your cake and eat it too? |
| cord-310272-utqyuy0n | In this paper, we are interested in seeing"what is the process of appropriation of IT devices by individual and volitional users following negative disconfirmation? |
| cord-310272-utqyuy0n | We seek to understand"what is the process of appropriation of IT devices by individual and volitional users following negative disconfirmation? |
| cord-310272-utqyuy0n | What happens when learning takes place? |
| cord-310272-utqyuy0n | What's under construction Here? |
| cord-310272-utqyuy0n | Why should I follow your rules? |
| cord-356040-qdpkidn8 | : what is the evidence? |
| cord-356040-qdpkidn8 | A call for action Should biologics for psoriasis be interrupted in the era of COVID-19? |
| cord-356040-qdpkidn8 | The protective and pathogenic roles of IL-17 in viral infections: friend or foe? |
| cord-356040-qdpkidn8 | the epidemic and the challenges COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? |
| cord-348244-1py0k53e | -what is it and what can it tell us? |
| cord-348244-1py0k53e | Transforming Clinical Research in the United States Randomized clinical trials- removing unnecessary obstacles The value of source data verification in a cancer clinical trial Risk- adapted monitoring is not inferior to extensive on- site monitoring: results of the ADAMON cluster- randomised study Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched- pair study A randomized evaluation of on- site monitoring nested in a multinational randomized trial Validation of a riskassessment scale and a risk- adapted monitoring plan for academic clinical research studies- the Pre- Optimon study Improving the quality of drug research or simply increasing its cost? |
| cord-338588-rc1h4drd | Chemotherapy in the treatment of Leukemia and Wilms'tumor Women in academic medicine leadership: has anything changed in 25 years? |
| cord-338588-rc1h4drd | How has healthcare research performance been assessed? |
| cord-338588-rc1h4drd | The gender gap in peer- reviewed publications by physical therapy faculty members: a productivity puzzle Comparison of evidence of treatment effects in randomized and nonrandomized studies Can the pharmaceutical industry reduce attrition rates? |
| cord-338588-rc1h4drd | Why are n't there more women leaders in academic medicine? |
| cord-344705-co0nk7pt | Aside from the important resource issue and the ethical issue of having to enrol so many patients in small, individual control groups, we raise another obvious concern: can these trials possibly deliver? |
| cord-344705-co0nk7pt | Could we have gleaned more useful information from the fate of those same 61 patients by including them in a well- coordinated multi- arm trial? |
| cord-344705-co0nk7pt | Even early on during the pandemic, the question has rightly been asked"Do we need 300 trials? |
| cord-344705-co0nk7pt | However, as drug regulators, we ask: how many of the ongoing trials will be able to support robust regulatory( and individual treatment) decisions? |
| cord-344705-co0nk7pt | Is that a good use of resources? |
| cord-344705-co0nk7pt | Is this condition met by a small,( underpowered) standalone trial, perhaps with a high probability of failure due to lack of enrolment? |
| cord-344705-co0nk7pt | Or could the objective be better met by redirecting the energy to one of the larger ongoing trials? |
| cord-344705-co0nk7pt | Why has this not happened to a larger extent and what are the possible reasons behind the fragmented trial landscape, globally and in the EU? |
| cord-344705-co0nk7pt | authors: Eichler, Hans‐Georg; Cavaleri, Marco; Enzmann, Harald; Scotti, Francesca; Sepodes, Bruno; Sweeney, Fergus; Vamvakas, Spiros; Rasi, Guido title: Clinical trials for Covid‐19: can we better use the short window of opportunity? |
| cord-269716-x3b0qphd | A comparison across six primate species Rapid cognitive flexibility of rhesus macaques performing psychophysical task- switching Is the top object adequately supported by the bottom object? |
| cord-269716-x3b0qphd | A test trial began as soon as the experimenter verbally prompted children to interact with the apparatus(''Can you get the ball?"). |
| cord-269716-x3b0qphd | Although children removed fewer straws in Phase 2 as compared with Phase 1, did they consistently remove the fewest possible number( i.e., two straws)? |
| cord-269716-x3b0qphd | As with Phase 1, the experimenter made statements only to encourage children's engagement( e.g.,''Can you get the ball?"). |
| cord-269716-x3b0qphd | Copy me or copy you? |
| cord-269716-x3b0qphd | For instance, some participants would recognize the change of the tube arrangement and say,''Why is the ball all the way down there?"or''How did you do that? |
| cord-269716-x3b0qphd | For instance, some participants would recognize the change of the tube arrangement and say,''Why is the ball all the way down there?"or''How did you do that? |
| cord-269716-x3b0qphd | How do you think you could get it out?";''If you get the ball, you'll get a sticker!"). |
| cord-269716-x3b0qphd | Like 3-year- olds, 4-year- olds'comments referred to the change of task configuration( e.g.,''There's only two straws";''Hey, it's now down there") and the experimenter's causation of the change( e.g.,''How did you do that?"), but 4-year- olds also commented on how this change affected their own behavior and success |
| cord-269716-x3b0qphd | Most 3-year- olds'comments reflected the change in task configuration( e.g.,''Why did it go down to this one?";''It's not up there anymore"), whereas other comments highlighted the configuration change but also flagged the experimenter's agency in causing that change( e.g.,''Why did you put two?";''How did you do that?"). |
| cord-269716-x3b0qphd | Most 3-year- olds'comments reflected the change in task configuration( e.g.,''Why did it go down to this one?";''It's not up there anymore"), whereas other comments highlighted the configuration change but also flagged the experimenter's agency in causing that change( e.g.,''Why did you put two?";''How did you do that?"). |
| cord-269716-x3b0qphd | Most 3-year- olds'comments reflected the change in task configuration( e.g.,''Why did it go down to this one?";''It's not up there anymore"), whereas other comments highlighted the configuration change but also flagged the experimenter's agency in causing that change( e.g.,''Why did you put two?";''How did you do that?"). |
| cord-269716-x3b0qphd | The start time for each trial began as soon as the experimenter uttered the introductory prompt(''Can you get the ball?") and ended once children indicated they were done removing straws by explicitly stating such or moving to Experimenter 2 to retrieve a sticker for ball retrieval( typically as soon as the ball fell from the tube). |
| cord-269716-x3b0qphd | Two- and three- year- olds reason about unseen events Inflexibility of experts- Reality or myth? |
| cord-269716-x3b0qphd | Where's the ball? |
| cord-269716-x3b0qphd | With each trial, Experimenter 1 verbally prompted children to retrieve the ball that came out of the tube(''Can you get the ball?") and told children that they would be rewarded with a sticker by Experimenter 2 when they obtained the ball(''Every time you give the ball to our friend[ Experimenter 2], you get a sticker!"). |
| cord-335198-qp964238 | And how do we quickly establish and conduct difficult and costly randomized, controlled clinical trials for the most promising old and new therapies where there is a clear equipoise between possible benefits and potential risks? |
| cord-335198-qp964238 | But how do we minimize the risks of progression in more severe hospitalized cases, particularly older patients with risk factor co- morbidities? |
| cord-335198-qp964238 | How did we rapidly implement a convalescent plasma program? |
| cord-335198-qp964238 | How do we best explore and exploit our overall clinical management and scientific research approach during the COVID19 pandemic? |
| cord-335198-qp964238 | How do we maximize compassionate use of available, potentially useful but unproven therapies when no other alternatives exist? |
| cord-335198-qp964238 | How do we minimize the risks of these very same therapies for individual patients? |
| cord-335198-qp964238 | How many patients? |
| cord-335198-qp964238 | How to adjust for confounder variables? |
| cord-335198-qp964238 | What disease severity? |
| cord-335198-qp964238 | What dose? |
| cord-335198-qp964238 | What to measure?, and how?, and why? |
| cord-335198-qp964238 | What to measure?, and how?, and why? |
| cord-335198-qp964238 | What to measure?, and how?, and why? |
| cord-335198-qp964238 | Which drugs to trial? |
| cord-335198-qp964238 | Which endpoints? |
| cord-335198-qp964238 | Which patients? |
| cord-335198-qp964238 | Whose needs are being met? |
| cord-335198-qp964238 | Why have n't others delivered more results? |
| cord-005705-j765ruj1 | -Clinical trials should be appraised according to the ethical principle of distributive justice: what cost for what result? |
| cord-005705-j765ruj1 | Are we really reducing tidal volume- and should we? |
| cord-005705-j765ruj1 | As mentioned above, what makes the greatest contribution to clinical practice regarding the prevention of gastrointestinal bleeding in ICU patients:"discordant"metaanalyses of multiple RCTs[ 45, 46] or a well conducted cohort study[ 47]? |
| cord-005705-j765ruj1 | Assessing the use of activated protein C in the treatment of severe sepsis Is academic medicine for sale? |
| cord-005705-j765ruj1 | But how generalizable are the data generated by RCTs with excellent internal validity but limited external validity? |
| cord-005705-j765ruj1 | California's new law allowing surrogate consent for clinical research involving subjects with impaired decision- making capacity Suspension of the NIH ARDS Network fluids and catheters treatment trial Control group selection in critical care randomized controlled trials evaluating interventional strategies: an ethical assessment Beyond randomised versus observational studies How best to ventilate? |
| cord-005705-j765ruj1 | Do surrogate decision makers provide accurate consent for intensive care research? |
| cord-005705-j765ruj1 | Does it make ethical sense to distress family members by asking them to consent to yet another study on SDD or on the prevention of gastrointestinal bleeding? |
| cord-005705-j765ruj1 | Finally, will the lack of effect of prone positioning on mortality in RCTs[ 37] discourage clinicians from using this very inexpensive and effective maneuver to improve patient oxygenation, and will these clinicians continue to await an RCT providing"proof"of efficacy[ 30]? |
| cord-005705-j765ruj1 | How many studies will be needed to convince clinicians to use a method they do not want to use? |
| cord-005705-j765ruj1 | How useful are RCTs in critically ill patients? |
| cord-005705-j765ruj1 | Intermittent positive- pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats Improved prognosis of acute respiratory distress syndrome 15 years on Searching for evidence: do n't forget the foundations Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials Selective digestive decontamination: for everyone, everywhere? |
| cord-005705-j765ruj1 | Is informed consent always necessary for randomized, controlled trials? |
| cord-005705-j765ruj1 | Medicine based evidence, a prerequisite for evidence based medicine Truth survival in clinical research: an evidence- based requiem? |
| cord-005705-j765ruj1 | Non- therapeutic research in the EU in adults incapable of giving consent? |
| cord-005705-j765ruj1 | Or shall we wait until the"final"meta- analysis is"negative"and"proves"that clinicians were right when they refused to use SDD despite the accumulation of so- called evidence? |
| cord-005705-j765ruj1 | Safeguarding patients in clinical trials with high mortality rates Is the concept of informed consent applicable to clinical research involving critically ill patients? |
| cord-005705-j765ruj1 | The effect of waiving consent on enrollment in a sepsis trial Is informed consent always necessary for randomized controlled trials? |
| cord-005705-j765ruj1 | The integral role of clinical research in clinical care Is informed consent always necessary for randomized, controlled trials? |
| cord-005705-j765ruj1 | What ethical problems do RCTs raise in critically ill patients? |
| cord-005705-j765ruj1 | What have these multimilliondollar trials contributed? |
| cord-005705-j765ruj1 | What is best for ARDS management? |
| cord-005705-j765ruj1 | What is the socioeconomic role of RCTs? |
| cord-005705-j765ruj1 | Why not evaluate new therapeutic interventions sequentially under conditions of genuine equipoise? |
| cord-005705-j765ruj1 | authors: Dreyfuss, Didier title: Is it better to consent to an RCT or to care?: |